RYVU Therapeutics S.A.
Clinical-stage company developing novel small molecule therapies for oncology.
RVU | WAR
Overview
Corporate Details
- ISIN(s):
- PLSELVT00013 (+2 more)
- LEI:
- 2594003WO9Q9HHAFL031
- Country:
- Poland
- Address:
- Kraków Leona Henryka Sternbacha 2, 30-394 Kraków
- Website:
- https://ryvu.com/
Description
Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-19 18:46 |
Notyfikacja Benevora Fundacja Rodzinna w organizacji
|
Polish | 80.6 KB | ||
| 2025-12-19 18:46 |
Notyfikacja Paweł Przewięźlikowski
|
Polish | 78.9 KB | ||
| 2025-12-19 18:46 |
Otrzymanie zawiadomienia w trybie art. 69 OfertPublU / Receipt of a notificatio…
|
English | 1.8 KB | ||
| 2025-12-19 18:46 |
Otrzymanie zawiadomienia w trybie art. 69 OfertPublU / Receipt of a notificatio…
|
Polish | 1.2 KB | ||
| 2025-12-10 18:45 |
Notyfikacja Benevora Fundacja Rodzinna
|
Polish | 8.9 KB | ||
| 2025-12-10 18:45 |
Notyfikacja Paweł Przewięźlikowski
|
Polish | 8.9 KB | ||
| 2025-12-10 18:45 |
Zawiadomienia od osoby pełniącej obowiązki zarządcze w Spółce / Notifications f…
|
English | 1.5 KB | ||
| 2025-12-10 18:45 |
Zawiadomienia od osoby pełniącej obowiązki zarządcze w Spółce / Notifications f…
|
Polish | 980 bytes | ||
| 2025-12-08 14:10 |
Prezentacja danych klinicznych dotyczących romacyklibu (RVU120) z badania REMAR…
|
English | 5.4 KB | ||
| 2025-12-08 14:10 |
Prezentacja danych klinicznych dotyczących romacyklibu (RVU120) z badania REMAR…
|
Polish | 5.6 KB | ||
| 2025-12-07 14:10 |
Nowe dane kliniczne z badań romacyklibu (RVU120) RIVER-81 i POTAMI-61 prezentow…
|
English | 7.8 KB | ||
| 2025-12-07 14:10 |
Nowe dane kliniczne z badań romacyklibu (RVU120) RIVER-81 i POTAMI-61 prezentow…
|
Polish | 8.5 KB | ||
| 2025-11-25 16:00 |
Terminy przekazywania raportów okresowych w 2026 roku / Publication dates for p…
|
English | 1.3 KB | ||
| 2025-11-25 16:00 |
Terminy przekazywania raportów okresowych w 2026 roku / Publication dates for p…
|
Polish | 903 bytes | ||
| 2025-11-20 17:09 |
Sprawozdanie Zarządu Q3 2025 EN
|
English | 4.1 MB |
Automate Your Workflow. Get a real-time feed of all RYVU Therapeutics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RYVU Therapeutics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RYVU Therapeutics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
